Insmed Incorporated (INSM) Given Average Recommendation of “Hold” by Brokerages
Shares of Insmed Incorporated (NASDAQ:INSM) have earned a consensus rating of “Hold” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $37.25.
A number of research analysts have weighed in on INSM shares. Zacks Investment Research downgraded Insmed from a “hold” rating to a “sell” rating in a report on Wednesday, February 28th. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Insmed in a research report on Thursday, January 4th. Robert W. Baird restated a “positive” rating and issued a $42.00 price target (up previously from $32.00) on shares of Insmed in a research report on Thursday, January 4th. Credit Suisse Group initiated coverage on Insmed in a research report on Wednesday, January 17th. They issued a “neutral” rating and a $31.00 price target for the company. Finally, ValuEngine upgraded Insmed from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd.
A number of institutional investors and hedge funds have recently modified their holdings of INSM. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Insmed by 137.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,662 shares of the biopharmaceutical company’s stock worth $145,000 after buying an additional 2,698 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in Insmed in the fourth quarter worth about $188,000. Prudential Financial Inc. purchased a new stake in Insmed in the third quarter worth about $232,000. Jefferies Group LLC purchased a new stake in Insmed in the fourth quarter worth about $245,000. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Insmed in the third quarter worth about $256,000. Institutional investors and hedge funds own 99.10% of the company’s stock.
Insmed (NASDAQ:INSM) last posted its earnings results on Friday, February 23rd. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.18). equities research analysts forecast that Insmed will post -3.65 EPS for the current year.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.